Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Overview Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Companies Involved in Therapeutics Development AbbVie Inc Apexigen Inc Apogenix AG BioNTech AG Boehringer Ingelheim GmbH Celldex Therapeutics Inc Denceptor Therapeutics Ltd F. Hoffmann-La Roche Ltd Johnson & Johnson Kyowa Hakko Kirin Co Ltd Novartis AG Seattle Genetics Inc Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Drug Profiles 2C-10 - Drug Profile Product Description Mechanism Of Action R&D Progress ABBV-428 - Drug Profile Product Description Mechanism Of Action R&D Progress ABBV-927 - Drug Profile Product Description Mechanism Of Action R&D Progress APG-1233 - Drug Profile Product Description Mechanism Of Action R&D Progress APX-005M - Drug Profile Product Description Mechanism Of Action R&D Progress BI-655064 - Drug Profile Product Description Mechanism Of Action R&D Progress Bispecific Monoclonal Antibody to Agonize CD40 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress bleselumab - Drug Profile Product Description Mechanism Of Action R&D Progress CDX-1140 - Drug Profile Product Description Mechanism Of Action R&D Progress CFZ-533 - Drug Profile Product Description Mechanism Of Action R&D Progress ChiLob-7/4 - Drug Profile Product Description Mechanism Of Action R&D Progress DNP-005 - Drug Profile Product Description Mechanism Of Action R&D Progress emactuzumab + RG-7876 - Drug Profile Product Description Mechanism Of Action R&D Progress FFP-104 - Drug Profile Product Description Mechanism Of Action R&D Progress JNJ-7107 - Drug Profile Product Description Mechanism Of Action R&D Progress KGYY-15 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies to Agonize CD40 and FCGR2B for B-cell Lymphoma and Melanoma - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody Conjugate to Target CD40 for Pancreatic Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress RG-7876 + vanucizumab - Drug Profile Product Description Mechanism Of Action R&D Progress SEA-CD40 - Drug Profile Product Description Mechanism Of Action R&D Progress selicrelumab - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile Product Description Mechanism Of Action R&D Progress Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Dormant Products Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Discontinued Products Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Product Development Milestones Featured News & Press Releases Nov 30, 2017: Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors Nov 07, 2017: Results from Alligator Biosciences clinical phase I study support further clinical development of ADC-1013 Oct 31, 2017: Apexigen Announces Late-Breaking Oral Presentation for Immune Activating Antibody APX005M at the 2017 Society for Immunotherapy of Cancer Annual Meeting Oct 25, 2017: Apexigen Announces New Collaboration with UCSF Sep 21, 2017: Alligator Bioscience to present ADC-1013 intratumoral clinical phase I study results at SITC in November 2017 Sep 20, 2017: The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute Announce First Patients Treated in Pancreatic Cancer Clinical Trial Combining Immunotherapy and Chemotherapy Jul 17, 2017: Apexigen Announces First Patient Dosed in Phase 1b/2 Clinical Trial of APX005M in Combination with Opdivo (nivolumab) in Advanced Solid Tumors May 10, 2017: Boehringer Ingelheim Phase II trial Now Enrolling Patients with the Kidney Disease Lupus Nephritis May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ADC-1013 Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ADC-1013 at PEGS conference in Boston, May 4 Apr 03, 2017: Phase I Clinical Trial Completes Using Cell Line Expertise at Cobra Biologics Mar 23, 2017: Alligator announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013 Mar 21, 2017: Phase 1/2 Clinical Trial of Apexigen’s APX005M in Combination with Pembrolizumab (Keytruda) Opens for Metastatic Melanoma Patients Dec 05, 2016: Celldex Presents Data on CDX-1140, a Novel CD40 Agonist Antibody for Hematologic and Solid Malignancies, at the American Society of Hematology Annual Meeting Nov 14, 2016: Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Indications, H1 2018 Number of Products under Development by Indications, H1 2018 (Contd..1), H1 2018 Number of Products under Development by Indications, H1 2018 (Contd..2), H1 2018 Number of Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 Products under Development by Companies, H1 2018 (Contd..1), H1 2018 Products under Development by Companies, H1 2018 (Contd..2), H1 2018 Products under Development by Companies, H1 2018 (Contd..3), H1 2018 Number of Products under Investigation by Universities/Institutes, H1 2018 Products under Investigation by Universities/Institutes, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Stage and Route of Administration, H1 2018 Number of Products by Stage and Molecule Type, H1 2018 Pipeline by AbbVie Inc, H1 2018 Pipeline by Apexigen Inc, H1 2018 Pipeline by Apogenix AG, H1 2018 Pipeline by BioNTech AG, H1 2018 Pipeline by Boehringer Ingelheim GmbH, H1 2018 Pipeline by Celldex Therapeutics Inc, H1 2018 Pipeline by Denceptor Therapeutics Ltd, H1 2018 Pipeline by F. Hoffmann-La Roche Ltd, H1 2018 Pipeline by Johnson & Johnson, H1 2018 Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2018 Pipeline by Novartis AG, H1 2018 Pipeline by Seattle Genetics Inc, H1 2018 Dormant Products, H1 2018 Dormant Products, H1 2018 (Contd..1), H1 2018 Discontinued Products, H1 2018 List of Figures Number of Products under Development by Stage of Development, H1 2018 Number of Products under Development by Therapy Areas, H1 2018 Number of Products under Development by Top 10 Indications, H1 2018 Number of Products by Mechanism of Actions, H1 2018 Number of Products by Stage and Mechanism of Actions, H1 2018 Number of Products by Routes of Administration, H1 2018 Number of Products by Stage and Routes of Administration, H1 2018 Number of Products by Molecule Types, H1 2018 Number of Products by Stage and Molecule Types, H1 2018

AbbVie Inc Apexigen Inc Apogenix AG BioNTech AG Boehringer Ingelheim GmbH Celldex Therapeutics Inc Denceptor Therapeutics Ltd F. Hoffmann-La Roche Ltd Johnson & Johnson Kyowa Hakko Kirin Co Ltd Novartis AG Seattle Genetics Inc